CAR-T challenges patent rules

Posted 21 December 2021 AM

There are three CAR-T Cell treatments approved by the TGA and two that are reimbursed by the federal government, yet concerns are raised that Australia's patent system may not be adequate for the new technology.

CAR-T Cell treatments involve isolating a patient's T-cells, modifying them with chimeric antigen receptors to become CAR-T cells, then infusing them into the patient where they attack cancer cells.

To see the whole article, please login